GADD 45β (G-11): sc-377311



The Power to Question

BACKGROUND

Cell cycle progression is subject to arrest at G_1 and G_2 checkpoints in response to DNA damage, presumably to allow time for DNA repair prior to entry into S and M phase, respectively. The p53 tumor suppressor is required for one such G_1 checkpoint and functions to upregulate expression of GADD 45 and p21. GADD 45 binds both Cdks and PCNA, a protein involved in DNA replication and repair. GADD 45 stimulates DNA excision repair *in vitro* and in hibits entry of cells into S phase. Thus, it has been suggested that GADD 45 may serve as a link between the p53-dependent cell cycle checkpoint and DNA repair. GADD 45-like proteins, GADD 45 β and GADD 45 γ , have been shown to be induced by environmental stresses. GADD 45 β and GADD 45 γ are thought to induce p38/JNK activation via MEKK4 activation.

CHROMOSOMAL LOCATION

Genetic locus: GADD45B (human) mapping to 19p13.3; Gadd45b (mouse) mapping to 10 C1.

SOURCE

GADD 45 β (G-11) is a mouse monoclonal antibody specific for an epitope mapping between amino acids 133-160 at the C-terminus of GADD 45 β of human origin.

PRODUCT

Each vial contains 200 μg IgM kappa light chain in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin.

Blocking peptide available for competition studies, sc-377311 P, (100 μ g peptide in 0.5 ml PBS containing < 0.1% sodium azide and 0.2% stabilizer protein).

APPLICATIONS

GADD 45 β (G-11) is recommended for detection of GADD 45 β of mouse, rat and human origin by Western Blotting (starting dilution 1:100, dilution range 1:100-1:1000), immunoprecipitation [1-2 μ g per 100-500 μ g of total protein (1 ml of cell lysate)], immunofluorescence (starting dilution 1:50, dilution range 1:50-1:500) and solid phase ELISA (starting dilution 1:30, dilution range 1:30-1:3000).

GADD 45 β (G-11) is also recommended for detection of GADD 45 β in additional species, including equine, canine and bovine.

Suitable for use as control antibody for GADD 45 β siRNA (h): sc-37416, GADD 45 β siRNA (m): sc-37417, GADD 45 β siRNA (r): sc-270211, GADD 45 β shRNA Plasmid (h): sc-37416-SH, GADD 45 β shRNA Plasmid (m): sc-37417-SH, GADD 45 β shRNA Plasmid (r): sc-270211-SH, GADD 45 β shRNA (h) Lentiviral Particles: sc-37416-V, GADD 45 β shRNA (m) Lentiviral Particles: sc-37417-V and GADD 45 β shRNA (r) Lentiviral Particles: sc-270211-V.

Molecular Weight (predicted) of GADD 45β: 18 kDa.


Molecular Weight (observed) of GADD 45β: 18-27 kDa.


Positive Controls: Hep G2 cell lysate: sc-2227 or human GADD 45β transfected HEK293T whole cell lysate.

STORAGE

Store at 4° C, **DO NOT FREEZE**. Stable for one year from the date of shipment. Non-hazardous. No MSDS required.

DATA





GADD 45 β (G-11): sc-377311. Western blot analysis of GADD 45 β expression in non-transfected (**A**) and human GADD 45 β transfected (**B**) HEK293T whole cell bester.

GADD 45 β (G-11): sc-377311. Immunofluorescence staining of formalin-fixed HeLa cells showing nuclear and cytoplasmic localization.

SELECT PRODUCT CITATIONS

- Martin, G.G., et al. 2017. Loss of fatty acid binding protein-1 alters the hepatic endocannabinoid system response to a high-fat diet. J. Lipid Res. 58: 2114-2126.
- Do, H., et al. 2019. TFAP2C increases cell proliferation by downregulating GADD45B and PMAIP1 in non-small cell lung cancer cells. Biol. Res. 52: 35.
- 3. Wu, L., et al. 2021. Hepatic GADD 45 β promotes hyperglycemia and glucose intolerance through DNA demethylation of PGC-1 α . J. Exp. Med. 218: e20201475.
- 4. Hanrui, Y., et al. 2022. Intermittent leucine deprivation produces longlasting improvement in Insulin sensitivity by increasing hepatic Gcn2 expression. Diabetes 71: 206-218.
- Singh, M., et al. 2022. Hydrogen sulfide mitigates skeletal muscle mitophagy-led tissue remodeling via epigenetic regulation of the gene writer and eraser function. Physiol. Rep. 10: e15422.
- 6. Hu, H.L., et al. 2022. Single-cell transcriptomics identifies GADD 45 β as a regulator of herpesvirus-reactivating neurons. EMBO Rep. 23: e53543.

RESEARCH USE

For research use only, not for use in diagnostic procedures.

PROTOCOLS

See our web site at www.scbt.com for detailed protocols and support products.

Santa Cruz Biotechnology, Inc. 1.800.457.3801 831.457.3801 fax 831.457.3801 Europe +00800 4573 8000 49 6221 4503 0 www.scbt.com